Dolatabadi S et al. [68] have found that a subpopulation with cancer stem cell (CSC) characteristics existed in MLS and that JAK-STAT signaling was active in MLS cell lines and regulated CSC characteristics, leading to the development of drug resistance in the tumor cells; the use of ruxolitinib, an inhibitor of JAK-STAT, can reduce the number of CSC-characteristic chemoresistant cells. This evidence concerns the gene SOAT1 and cancer.